Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or N… (NCT00083213) | Clinical Trial Compass
CompletedPhase 1
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
United States25 participantsStarted 2004-01
Plain-language summary
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating patients with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.
Who can participate
Age range18 Years – 120 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed diagnosis of one of the following:
* Non-Hodgkin's lymphoma
* Primary or metastatic solid tumor located, by radiography, in at least one of the following sites:
* Liver
* Soft tissue
* Pelvis
* Other site that is suitable for delayed contrast-enhanced MRI (e.g., peripheral lung field)
* Relapsed or refractory (including unresectable) disease
* Patients with solid tumors must have failed all curative chemotherapeutic regimens
* Patients with non-Hodgkin's lymphoma must be refractory to at least 2 standard chemotherapeutic regimens and rituximab
* Not amenable to available conventional therapies AND no standard therapy exists
* Measurable disease
* No prior or concurrent CNS metastases (brain or leptomeningeal)
* No primary intracranial tumor by MRI or CT scan
* No histologically confirmed squamous cell carcinoma of the lung
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* ECOG 0-2
Life expectancy
* Not specified
Hematopoietic
* WBC ≥ 3,500/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
* Hemoglobin ≥ 9.0 g/dL
* Platelet count ≥ 100,000/mm\^3
* No severe or uncontrolled hematologic condition
Hepatic
* Bilirubin ≤1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 2.5 times ULN
* PT and PTT normal
* INR normal
* Hepatitis B surface antigen negative
* Hepatitis C antibody negative
Renal
* Creatinine ≤ ULN
* Urine protein/creatinine ratio ≤ 1
* No severe or uncontrolled r…